Qyuns Therapeutics
Qyuns Therapeutics develops monoclonal antibody drugs for autoimmune diseases.
Business Model:
Revenue: $0
Employees: 51-200
Rankings
Industries / Tags:
Detailed Qyuns Therapeutics Information
Geographic Data
Address:
City: Taizhou
State: Jiangsu
Zip:
Country: China
Financial Info
Stage:
series c
Raised Last:
$16M
Raised Total:$36M
Social
Metrics
8,755,617Website Global Rank
261Website Monthly Traffic
Twitter Followers
Description
Qyuns is developing six candidates, most of them interleukin antibodies. It has two biosimilar drugs in China clinical trials, including a biosimilar to tocilizumab, a Chugai drug marketed as Actemra for various rheumatoid arthritis conditions.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 3/2022 | Series C | 2 | $15.8M |
Shenzhen Kaiding Juncan venture Cci Capital TriWise Capital Shenzhen Kaiding Juncan venture Cci Capital TriWise Capital |
5/2020 | Series B | 2 | - |
Jiayin Investment Lucky Source Funds Jiayin Investment Lucky Source Funds |
7/2019 | Series B | 3 | $20M |
Hefu Ruitai Hongtai Capital Holdings TriWise Capital Hefu Ruitai Hongtai Capital Holdings TriWise Capital |
5/2020 | Series B | 2 | - |
Jiayin Investment Lucky Source Funds Jiayin Investment Lucky Source Funds |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
